BJMO - volume 16, issue 6, october 2022
G. Nader-Marta MD, F.P. Duhoux MD, PhD, D. Taylor MD, T. Van den Mooter MD, H. Denys MD, PhD, J-L. Canon MD, J. Mebis MD, A. Awada MD, PhD, H. Wildiers MD, PhD, K. Punie MD, E. de Azambuja MD, PhD
HER2-targeted agents are the central component of HER2-positive metastatic breast cancer (MBC) treatment. The combination of trastuzumab, pertuzumab and a taxane is the preferred first-line regimen in most settings. For patients with disease relapse after adjuvant therapy, treatment decisions in the first-line are influenced by the treatment-free interval and the regimens used in the (neo)adjuvant setting. T-DXd has been recently established as the preferred second-line therapy. T-DM1, or the combination of tucatinib, trastuzumab and capecitabine, are reasonable third-line options, although efficacy and safety data of these regimens after prior exposure to T-DXd are lacking. In fourth and later lines, trastuzumab duocarmazine, neratinib plus capecitabine, margetuximab plus chemotherapy, lapatinib-based combinations or the continuation of trastuzumab with different chemotherapy partners are valid alternatives.
(BELG J MED ONCOL 2022;16(6): 287–92)
Read moreBJMO - volume 15, issue 7, november 2021
X. Mortiers MD, H. Vandeursen MD, PhD, T. Adams MD, T. Van den Mooter MD
Prostate cancer (PCa) is the most common cancer in men and the second leading cause of cancer death in men worldwide. Frequent metastatic sites of PCa are bone, lung, liver, pleura and adrenal gland. We hereby present a case of a 70-year old man with a history of prostate adenocarcinoma, treated with external beam radiotherapy, who consulted his urologist with a painful left hemiscrotum. An ultrasound showed a suspicious lesion in his left testis. Pathology of the orchidectomy specimen revealed a metastatic deposit of his prostate adenocarcinoma.
(BELG J MED ONCOL 2021;15(7):380-2)
Read moreBJMO - volume 13, issue 4, june 2019
X. Mortiers MD, H. Vandeursen MD, PhD, T. Adams MD, T. Van den Mooter MD
Breast cancer often metastasises to bone, lymph nodes, liver and lung. In this case report, we present a 75-year-old woman with a suspicious mammography and ultrasound of the breast who had a synchronous painless renal lesion. On computed tomography, the renal mass was suspected of being a primary lesion of the renal pelvis, but anatomopathological examination of the nephro-ureterectomy specimen revealed that it was a metastatic deposit of invasive lobular adenocarcinoma of the breast.
(BELG J MED ONCOL 2019;13(4):132–134)
Read moreBJMO - volume 13, issue 1, february 2019
Ir A. Hébrant PhD, Ir , A. Jouret-Mourin MD, PhD, G. Froyen PhD, J. Van der Meulen MD, M. De Man MD, R. Salgado MD, PhD, M. van den Eynde MD, PhD, N. D’Haene MD, PhD, G. Martens MD, PhD, E. van Cutsem MD, PhD, H.A. Poirel MD, PhD, S. Tejpar MD, PhD, J-L. van Laethem MD, PhD, K. Geboes MD, P. Pauwels MD, PhD, F. Dedeurwaerdere MD, B. Maes MD, PhD, J. De Grève MD, PhD, J. Vanhuysse , P. Peeters MD, L. Vanacker MD, M. Gomez-Galdon , M. Chintinne MD, PhD, A. Hendlisz MD, PhD, G. de Hertogh MD, PhD, X. Sagaert MD, PhD, M. Peeters MD, PhD, P. Vannuffel , P. Lefesvre MD, PhD, J. Vermeij , M. Simoens , T. Van den Mooter MD, N. van Damme PhD, M. Van den Bulcke PhD
The Belgian Commission of Personalized Medicine has been created to advise the federal government on all matters related to personalised medicine in oncology, including the reimbursement of molecular tests. Here, we propose the Belgian strategy for molecular testing in the digestive tumours within a scientific-based framework. For each tested biomarker, a clinical test level is attached, which is key to establish the relevance of the test and to define the reimbursement. For each digestive tumour type, the different molecular tests are represented as decision trees with its test utility, test level and a brief technical test description.
(BELG J MED ONCOL 2019;13(1):4–10)
Read moreBJMO - 2017, issue 3, february 2017
T. Van den Mooter MD, S. Van Hecke , I. Huyghe , T. Chapelle , M. Peeters MD, PhD
BJMO - volume 10, issue 5, august 2016
K. Papadimitriou MD, PhD, T. Van den Mooter MD, J. Van den Brande MD, M. Rasschaert MD, PhD, M. Peeters MD, PhD
During the 2016 ASCO Annual Meeting, a robust body of phase III trials was presented in the gastrointestinal (GI) oncology field, including updates and interesting post-hoc analyses. Once more, the early phase research was mainly focused on immunotherapy, with some promising results.
(BELG J MED ONCOL 2016;10(5):150–155)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
